Amgen Inc.'s stock gained ground as investors listened to pundits give forth their opinions on federal reimbursement changes disclosed Friday for the high-selling Aranesp (darbepoetin alfa) and Epogen (epoetin alfa), when used in kidney disease. (BioWorld Today)